Citadel Advisors
VTGN icon

Citadel Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Citadel Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Sell
239,200
-147,400
-38% -$89.6K ﹤0.01% 11767
2025
Q4 		$256K Buy
386,600
+144,000
+59% +$520K ﹤0.01% 10499
2025
Q3 		$861K Buy
242,600
+175,500
+262% +$524K ﹤0.01% 7863
2025
Q2 		$134K Buy
67,100
+58,200
+654% +$132K ﹤0.01% 11061
2025
Q1 		$22.3K Sell
8,900
-2,300
-21% -$6.51K ﹤0.01% 13066
2024
Q4 		$33K Sell
11,200
-2,800
-20% -$7.88K ﹤0.01% 12781
2024
Q3 		$42.1K Sell
14,000
-33,200
-70% -$113K ﹤0.01% 12094
2024
Q2 		$164K Sell
47,200
-5,600
-11% -$24.3K ﹤0.01% 10205
2024
Q1 		$279K Buy
52,800
+17,900
+51% +$86.1K ﹤0.01% 9606
2023
Q4 		$179K Buy
34,900
+25,100
+256% +$95K ﹤0.01% 10107
2023
Q3 		$51.4K Buy
+9,800
New +$43.5K ﹤0.01% 11733
2023
Q1 		– Sell
-397
Closed -$1.23K – 15589
2022
Q4 		$1.23K Sell
397
-3,123
-89% -$11.8K ﹤0.01% 14507
2022
Q3 		$16K Buy
3,520
+277
+9% +$2.75K ﹤0.01% 12151
2022
Q2 		$86K Buy
3,243
+2,280
+237% +$80.5K ﹤0.01% 11543
2022
Q1 		$36K Buy
963
+203
+27% +$8.85K ﹤0.01% 13004
2021
Q4 		$44K Buy
+760
New +$49.5K ﹤0.01% 13319

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's VTGN Position: Q4 2025 in Review

Citadel Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 122,062 shares — an estimated $441K sold.

Citadel Advisors first reported a position in VTGN in Q3 2017 and held it in 18 quarters. The position peaked at $3.93M in Q1 2024. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Citadel Advisors reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 122,062 VistaGen Therapeutics shares in Q4 2025, an estimated $441K.
  • Citadel Advisors first reported a position in VistaGen Therapeutics in Q3 2017 and held it in 18 quarters.
  • Citadel Advisors's VistaGen Therapeutics position peaked at $3.93M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.